8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported) – February 7, 2012

WEST PHARMACEUTICAL SERVICES INC.

(Exact name of registrant as specified in its charter)

Pennsylvania	1-8036	23-1210010
(State or other jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
101 Gordon Drive, PO Box 645, Lionville, PA		19341-0645
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: 610-594-2900

Not Applicable

(Former name or address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  

Item 7.01. Regulation FD Disclosure

On February 7, 2012, our management will present at the UBS 22nd Annual Global Healthcare Services Conference in New York, New York at 3:00 PM ET.

A copy of the Company’s presentation materials from the conference will be available for 30 days through the Investors link at the Company’s website, http://www.westpharma.com, and is also attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (Exchange Act) or otherwise subject to the liabilities of that section, nor will it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referencing in such filing.

Item 9.01.  Financial Statements and Exhibits

(d)	Exhibits
	Exhibit 99.1	West Pharmaceutical Services, Inc. Overview (Investor Presentation).

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

WEST PHARMACEUTICAL SERVICES, INC.

/s/ John R. Gailey III

John R. Gailey III, Vice President, General

Counsel and Secretary

February 7, 2012

3

EXHIBIT INDEX

Exhibit No.	Description
99.1	West Pharmaceutical Services, Inc. Overview (Investor Presentation).

4

EX-99.1

WEST PHARMACEUTICAL SERVICES, INC.

Solutions for Injectable Drug DeliveryNYSE:WSTwww.westpharma.com

© 2012 by West Pharmaceutical Services, Inc., Lionville, PA.

All rights reserved. This material is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any
form or by any means, electronic, mechanical, photocopying or otherwise, without written permission of West Pharmaceutical Services, Inc.. All
trademarks and registered trademarks are property of West Pharmaceutical Services, Inc., unless noted otherwise.

UBS Global Healthcare Services Conference

New York, NY

February 7, 2012

Safe Harbor Statement

2

Cautionary Statement Under the Private Securities Litigation Reform Act of 1995

This presentation and any accompanying management commentary contain “forward-looking statements”
as that term is defined in the Private Securities Litigation Reform Act of 1995.Such statements include,
but are not limited to statements about expected financial results for 2011 and future years.

Each of these estimates is based on preliminary information, and actual results could differ from these
preliminary estimates.We caution investors that the risk factors listed under “Cautionary Statement” in
our press releases, as well as those set forth under the caption "Risk Factors" in our most recent Annual
Report on Form 10-K as filed with the Securities and Exchange Commission and as revised or
supplemented by our quarterly reports on Form 10-Q, could cause our actual results to differ materially
from those estimated or predicted in the forward-looking statements. You should evaluate any statement
in light of these important factors. Except as required by law or regulation, we undertake no obligation to
publicly update any forward-looking statements, whether as a result of new information, future events, or
otherwise.

Non-GAAP Financial Measures

Certain financial measures included in these presentation materials, and which may be referred to in
management’s discussion of the Company’s results and outlook, are Non-GAAP (Generally Accepted
Accounting Principles) financial measures. Please refer to the “Non-GAAP Financial Measures” and
“Notes to Non-GAAP Financial Measures” at the end of these materials for more information.Non-GAAP
financial measures should not be considered in isolation or as an alternative to such measures
determined in accordance with GAAP.

3

Pharmaceutical Packaging Systems

Pharmaceutical Delivery Systems

•Aglobally diverse manufacturer of
products used primarily in containing and
administering small-volume parenteral
drugs.

•Strong competitive position

–Substantial market shares

–Proprietary technology

–Diversified customer base

–Global footprint

–Preferred products for biologics

–Long-term customer relationships

•Stability with growth potential

•Proprietary Products

•Geographic Expansion

•Financial strength to invest

–Reliable operating cash flow

–Well capitalized

A Diverse, Stable Customer Base
(representative healthcare customers)

PHARMACEUTICAL / BIOTECHNOLOGY

6

GENERIC

MEDICAL DEVICE

Business Segments

5

$785

$324

2010 Revenues

($ millions)

Delivery Systems

•Contract manufacturing base

•Multi-material

•Project management

•Automated assembly

•Regulated products

•Capabilities + IP =proprietary
delivery devices

•Proprietary devices are
expected to drive growth

Packaging Systems

•Established leadership

•Designed-in revenue base

•Diverse global capabilities

•High market shares

•Steady growth in base

•Increasing unit value of products
and geographic expansion are
expected to enhance growth

Recent Highlights

•First nine months of 2011:

–Sales increased 4.5%, excluding currency

–Gross and operating margin compressed by material costs, currency

–Implemented mitigating surcharge mid-year

•Updated long-term financial targets in Q3 2011 release & analyst call

•4th Quarter, Full-Year 2011 results:Release date February 16, 2012

•China rubber facility under construction

•India land acquired

•Demand for contract manufacturing services better than 2010

•Vetter collaboration announced for CZ filling capacity

•Glass packaging compatibility issues generating strong interest in
alternative packaging materials, especially for biologics and other
high value drugs

6

2012 Outlook and Challenges

•Expect 4%-6% revenue growth in 2012, excluding currency

–Will provide more detailed expectations on February analyst call

•Pharmaceutical and Device markets:

–New product pipelines showing signs of strength

–Patent cliff front and center

–Shift to large molecule products continues

–Global shift in product sourcing (e.g., India generic growth)

–More demanding regulatory environment

•Continuing Fx and commodity price volatility

–Euro, European growth and sovereign debt

–Oil and regional political, civil and military turmoil

–Less predictable demand

7

•Company: Demographics, increasing prevalence of chronic disease,
increasing use of biologics to treat those diseases, better access to
healthcare

What will drive growth?

8

•Packaging Systems Segment –Growth in emerging markets –Escalating regulatory and
quality demands •Delivery Systems Segment –Growth in combination
products that promote safety,
dosing accuracy, ease of use,
and deliver cost savings and
product differentiation –Increasing awareness of
glass quality issues –Adding plants: China, India –Expanding Westar® and
Envision® capacity,
introducing NovaPure®
components –SmartDose®electronic patch
injector platform technology –ConfiDose® auto-injector
platform technology –Reconstitution products –Safety syringes –Daikyo Crystal Zenith®
products

Daikyo Crystal Zenith® is a registered trademark of Daikyo Seiko, Ltd.

Category	Key Customers	Projected Growth
Diabetes		> 10 %
Oncology		> 10 %
Vaccines		> 10 %
Autoimmune		>8%
Generics		>10%

IMS April 2010 Report; Business Insights 2009; GBI Research 2009

9

Therapeutic Category Growth Drivers

Packaging Segment Overview

1
0

2010 Revenue

($ millions)

Packaging Systems

•Market leader

•Strong recurring revenue base

•Global manufacturing

•Steady growth in base

•Future growth will be driven by:
added value per unit sold;
geographic expansion; and
growth in key therapeutic
segments

$785

Pharmaceutical Packaging SystemsPackaging Components for Small Volume Parenterals

Plungers, Tip caps,
Needle shields for Glass
Syringes

Plungers, lined seals
for Glass Cartridges
for Pens

11

Primary packaging components (those that touch the drug) are typically
proprietary to West andare “designed into” customers’ drug products

12

StandardHigh-Value
ProductsProducts

Revenue Opportunity ($ per unit)

Plungers and
sleeve stoppers

Stoppers

Seals

RU seals

Westar® RU

Faster Growth of High-Value ProductsPharmaceutical Packaging Systems

13

Delivery Systems Segment Overview

14

$324

•Contract manufacturing base

•Customer owned IP

•Project management

•Automated assembly

•Regulated products

•Proprietary Product
Development

•West owned IP

•Multiple use platforms

•Focus on unmet needs for
biologics

2010 Revenue

($ millions)

Delivery Systems

Daikyo Crystal Zenith®
Life-cycle Containment Solutions

15

West MixJect® and
Vial2Bag®

Custom Manufacturing of
Components and Devices

Proprietary Components, Devices and Systems

West ConfiDose®
auto-injector platform
technology

SmartDose® electronic
patch injector platform
technology

Daikyo Crystal Zenith® is a registered trademark of Daikyo Seiko, Ltd.

16

Revenue per-unit

Consumer product
manufacturing

Medical
device
manufacturing

Mix2Vial®

CZ vials

CZ Syringes

Effect of Increasing Proprietary Device Sales
Contract ManufacturingProprietary Devices
Products

Auto-injector platform
technology

Electronic patch
injector technology

Concerns With Glass Syringes

•Interaction with sensitive biologics

•Protein aggregation (silicone oil)

•Residual chemicals (tungsten, glue)

•Glass flakes

•Dimensional variation

•Variable silicone distribution

•High Cost of Quality

•Breakage

•In process/handling

•Within auto-injector systems

Siliconized Glass Syringe

Crystal Zenith Syringe

17

Daikyo CZ Solution
with Daikyo Flurotec® Barrier Film

•Reduces:

–drug exposure to extractables

–risk of protein aggregation caused by silicone oil in the drug product

–returns and in-process clean-ups caused by broken glass

–risk of delamination and glass-particulate contamination

•Consistent piston release and travel forces without using silicone oil

18

Flurotec® is a registered trademark of Daikyo Seiko, Ltd.

Pharma Industry Drug Life-Cycle
Management

Phase I

Phase II

Phase III

Post-Market Life Cycle Management

8 - 10 years

2 - 3 years

2 - 3 years

Regulatory

Approval

Discovery

19

SmartDose®
Electronic Patch Injector Technology Platform

Programmed by PDA or PC

Dose may be customized

Applied and activated by patient

20

•Controlled, subcutaneous, micro-infusion delivery
of high volumes and high viscosity drugs

•Prefilled cartridge, no need for user filling

•Based on Daikyo CZ cartridge

•Compact

•Hidden needle for safety

•Single push-button operation

Prototype Operation

Our Long-Term Focus

•Pharmaceutical Packaging Systems

–Organic growth of 3-5% per year

–Margin expansion from efficiency, product mix

–Capital investments target enhanced quality and value

•Pharmaceutical Delivery Systems

–Deliver the potential of Daikyo CZ products

–Stronger mix of healthcare-consumable contract manufacturing

–Grow proprietary safety and delivery systems

•Financial discipline

–Operating cash flow supports R&D and capital spending

–Deliver returns (ROIC) that regularly exceed cost of capital (WACC)

–Maintain quarterly dividend

–Align incentives with financial performance and value creation

21

($ millions)	September 30, 2011	December 31, 2010
Cash and cash equivalents	$119.2	$110.2
Debt	$378.0	$358.4
Equity	$691.3	$625.7
Net debt to total invested capital	27.2%	28.4%
Working capital	$274.2	$266.9

Selected Financial Information

22

•Balance Sheet

•Dividend

−Most recent quarter: $0.18 per share ($0.72 annually at current rate)

− Annual increases for 18 consecutive years

23

Pharmaceutical Packaging Systems

Pharmaceutical Delivery Systems

•Strong competitive position

•Stability with growth potential

•New products well positioned to
meet future market needs

•The financial strength to invest

•2011 Year-End Analyst Call
February 16, 2012 at 9:00AM

Summary

WEST PHARMACEUTICAL SERVICES, INC.

Solutions for Injectable Drug DeliveryNYSE:WSTwww.westpharma.com

© 2012 by West Pharmaceutical Services, Inc., Lionville, PA.

All rights reserved. This material is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any
form or by any means, electronic, mechanical, photocopying or otherwise, without written permission of West Pharmaceutical Services, Inc.. All
trademarks and registered trademarks are property of West Pharmaceutical Services, Inc., unless noted otherwise.

UBS Global Healthcare Services Conference

New York, NY

February 7, 2012